Maria-Victoria Mateos

Melflufen and Dexamethasone Plus Bortezomib or Daratumumab in Relapsed/Refractory Multiple Myeloma Refractory to an IMiD or Proteasome Inhibitor: Updated Analysis of the Phase 1 ANCHOR Study (OP-104)

Purpose of the Study: Despite recent therapeutic advances, multiple myeloma (MM) remains incurable. Melflufen is a lipophilic peptide-conjugated alkylator that rapidly delivers a highly c...

Yvonne A. Efebera ;

Miquel Granell ;

Paul G. Richardson ;

Roman Hajek ;

Maria-Victoria Mateos ;

Albert Oriol ;

Jacques Delaunay ;

Katell Le Du ;

Jean-Richard Eveillard ;

Lionel Karlin ;

Vladimir Maisnar ;

Joaquin Martinez-Lopez ;

Maxim Norkin ;

Jan Staub ;

Catriona Byrne ;

Malin Sydvander ;

Enrique M. Ocio ;

Vincent Ribrag , MD;

Ludk Pour ;

10/22/2019

Precursors disorders in Myeloma: can we cure some of them?

Maria-Victoria Mateos ;

10/19/2018

Trial in Progress: Once-Weekly vs Twice-Weekly Dosing of Carfilzomib-Lenalidomide-Dexamethasone in Patients w/ Relapsed or Refractory Multiple Myeloma

Purpose of the Study: Carfilzomib (K), an irreversible proteasome inhibitor, is approved for the treatment of patients (pts) with relapsed or refractory  multiple  myeloma &nbsp...

Xavier Leleu ;

Meral Beksac ;

Maria-Victoria Mateos ;

Ludek Pour ;

Katja Weisel ;

Daniel Coriu ;

Mihaela Obreja ;

Amanda Goldrick ;

Meletios-Athanasios Dimopoulos ;

10/23/2019

Updated Efficacy and Safety of Melflufen in Patients with Relapsed/ Refractory Multiple Myeloma Refractory to Daratumumab and/or Pomalidomide: HORIZON (OP-106)

Purpose of the Study: Despite advances in therapy, MM remains incurable. Patients with late-stage relapsed/refractory multiple myeloma (RRMM) refractory to pomalidomide and/or daratumumab...

Hani Hassoun ;

Adrian Alegre ;

Christopher Maisel ;

Amitabha Mazumder ;

Jeffrey A. Zonder ;

Noemi Puig ;

John Harran ;

Sara Thuresson ;

Hanan Zubair ;

Albert Oriol ;

Agne Paner , MD;

Maxim Norkin ;